BioWorld

April 22, 2002

MedImmune Enters Licensing Deals For Two Cancer Products

MedImmune Inc. agreed to spend an undisclosed amount of money expanding its cancer program through the licensure of two early stage technologies. (BioWorld Today) Read More

Telik, Sanwa Kagaku Extend Collaboration For Third Time

Calcium Prescribed To Ward Off Osteoporosis In Postmenopause Netted Good’ Cholesterol Bonus

Coastal City’s Misnamed Crabs Supporting Device, Drug Safety

Other News To Note

Appointments And Advancements

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...